Human Immunology Biosciences (HI-Bio)

Executive Summary

Human Immunology Biosciences (HI-Bio) is a clinical-stage biotechnology company pioneering precision therapies for immune-mediated diseases by targeting specific plasma cells and effector B cells. Founded in 2022 and based in South San Francisco, the company has raised $95 million to advance its pipeline aimed at moving beyond broad immunosuppression to targeted immune modulation. HI-Bio's approach is particularly relevant for rare autoimmune and inflammatory conditions where pathogenic immune cell populations drive severe organ damage. The company's lead program is in Phase 2 development, with potential to address significant unmet needs in indications such as lupus nephritis, myasthenia gravis, or other antibody-driven diseases. With a focus on drugging discrete immune cell subsets, HI-Bio differentiates itself by aiming for improved efficacy and safety profiles compared to standard-of-care therapies.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data readout for lead asset in an immune-mediated indication40% success
• Q2 2026Regulatory feedback or IND clearance for a second program70% success
• H2 2026Potential partnership or licensing deal to expand pipeline or geographic reach50% success